Premium
S3‐Leitlinie zur Therapie der Psoriasis vulgaris – Update: „Übersicht der Therapieoptionen” und „Efalizumab”
Author(s) -
Nast Alexander,
Augustin Matthias,
Boehncke WolfHenning,
Klaus Joachim,
Mrowietz Ulrich,
Ockenfels HansMichael,
Philipp Sandra,
Reich Kristian,
Rosenbach Thomas,
Schlaeger Martin,
Sebastian Michael,
Sterry Wolfram,
Streit Volker,
Weisenseel Peter,
Rzany Berthold
Publication year - 2010
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2009.07312_supp.x
Subject(s) - philosophy , library science , art history , art , computer science
In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.